NO321658B1 - 3-Azabicyklo[3.1.0]heksanderivater som opiatreceptorligander - Google Patents

3-Azabicyklo[3.1.0]heksanderivater som opiatreceptorligander Download PDF

Info

Publication number
NO321658B1
NO321658B1 NO20013148A NO20013148A NO321658B1 NO 321658 B1 NO321658 B1 NO 321658B1 NO 20013148 A NO20013148 A NO 20013148A NO 20013148 A NO20013148 A NO 20013148A NO 321658 B1 NO321658 B1 NO 321658B1
Authority
NO
Norway
Prior art keywords
mmol
formula
azabicyclo
methyl
compound
Prior art date
Application number
NO20013148A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013148L (no
NO20013148D0 (no
Inventor
Bernard Joseph Banks
Stephen Paul Gibson
Robert James Crook
Graham Lunn
Alan John Pettman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828485.4A external-priority patent/GB9828485D0/en
Priority claimed from GBGB9912425.7A external-priority patent/GB9912425D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20013148D0 publication Critical patent/NO20013148D0/no
Publication of NO20013148L publication Critical patent/NO20013148L/no
Publication of NO321658B1 publication Critical patent/NO321658B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20013148A 1998-12-23 2001-06-22 3-Azabicyklo[3.1.0]heksanderivater som opiatreceptorligander NO321658B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9828485.4A GB9828485D0 (en) 1998-12-23 1998-12-23 Compounds useful in therapy
GBGB9912425.7A GB9912425D0 (en) 1999-05-27 1999-05-27 Compounds useful in therapy
PCT/IB1999/001852 WO2000039089A1 (fr) 1998-12-23 1999-11-19 Derives 3-azabicyclo[3.1.0] hexane utilises comme ligands de recepteurs d'opiaces
US09/467,871 US6313312B1 (en) 1998-12-23 1999-12-20 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy

Publications (3)

Publication Number Publication Date
NO20013148D0 NO20013148D0 (no) 2001-06-22
NO20013148L NO20013148L (no) 2001-08-23
NO321658B1 true NO321658B1 (no) 2006-06-19

Family

ID=27269601

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013148A NO321658B1 (no) 1998-12-23 2001-06-22 3-Azabicyklo[3.1.0]heksanderivater som opiatreceptorligander

Country Status (33)

Country Link
US (3) US6313312B1 (fr)
EP (1) EP1140828B1 (fr)
JP (1) JP3553886B2 (fr)
CN (1) CN1192021C (fr)
AP (1) AP1852A (fr)
AT (1) ATE335725T1 (fr)
AU (1) AU761574B2 (fr)
BG (1) BG65402B1 (fr)
BR (1) BR9916584A (fr)
CA (1) CA2356300C (fr)
CY (1) CY1106445T1 (fr)
CZ (1) CZ20012299A3 (fr)
DE (1) DE69932738T2 (fr)
DK (1) DK1140828T3 (fr)
DZ (1) DZ2962A1 (fr)
EA (1) EA004672B1 (fr)
ES (1) ES2274646T3 (fr)
HK (1) HK1041698B (fr)
HR (1) HRP20010477B1 (fr)
HU (1) HUP0104816A3 (fr)
ID (1) ID28981A (fr)
IL (1) IL142697A0 (fr)
IS (1) IS2467B (fr)
MA (1) MA25035A1 (fr)
NO (1) NO321658B1 (fr)
NZ (1) NZ511234A (fr)
OA (1) OA11727A (fr)
PL (1) PL348453A1 (fr)
SI (1) SI1140828T1 (fr)
SK (1) SK8772001A3 (fr)
TW (1) TWI244481B (fr)
UY (1) UY25873A1 (fr)
WO (1) WO2000039089A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての3−アザビシクロ(3.1.0)ヘキサン誘導体
MXPA05000434A (es) 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
US7265147B2 (en) * 2002-07-31 2007-09-04 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
DE60231341D1 (de) * 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409217A (pt) * 2003-04-09 2006-03-28 Pharmacia & Upjohn Co Llc derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona
WO2004089898A1 (fr) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
CN100436414C (zh) * 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
WO2004089908A2 (fr) * 2003-04-14 2004-10-21 Pfizer Products Inc. Derives de 3-azabicyclo[3.2.1]octane
MXPA06004278A (es) * 2003-10-16 2006-06-28 Pfizer Prod Inc Preparacion de derivados de 3-azabiciclo [3.1.0]hexano.
MX2007002136A (es) * 2004-09-01 2007-04-02 Pfizer Prod Inc Antagonistas amino azabiciclicos del receptor 3 de la histamina.
WO2006113458A1 (fr) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Inhibiteurs heterocycliques des proteines arginine methyle transferases
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型
GB0716632D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Compounds
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之8-氮雜雙環〔3.2.1〕辛基-2-羥基苯甲醯胺化合物
US7691878B2 (en) * 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029257A1 (fr) * 2007-08-27 2009-03-05 Theravance, Inc. Composes d'alkyl-8-azabicyclo[3.2.1.]octane disubstitutes utilises en tant qu'antagonistes du recepteur opioide mu
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
JP6041886B2 (ja) 2011-11-07 2016-12-14 スノヴィオン ファーマシューティカルズ インコーポレイテッドSunovion Pharmaceuticals Inc. オピオイド受容体の調節物質およびそれを含む薬学的組成物
AU2014354085B2 (en) 2013-11-20 2018-04-26 Ube Corporation Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes
WO2015117146A1 (fr) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Acides gamma-aminés bêta-substitués et analogues en tant qu'agents chimiothérapeutiques
EP3102195B1 (fr) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Acides bêta-aminés substitués en bêta et analogues en tant qu'agents de chimiothérapie
CN104177284B (zh) * 2014-08-01 2016-08-24 常州大学 合成3-氮杂二环[3,1,0]己基-1-甲醛的方法
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3299357A4 (fr) * 2015-05-20 2018-11-14 Sanwa Kagaku Kenkyusho Co., Ltd. Cristal de sel de nouveau dérivé de 3-azabicyclo[3.1.0]hexane et son utilisation pharmaceutique
WO2017024009A1 (fr) 2015-08-03 2017-02-09 Quadriga Biosciences, Inc. Acides bêta-aminés substitués en bêta et analogues à utiliser en tant qu'agents de chimiothérapie et leurs utilisations
WO2017121692A1 (fr) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Sulfamides substitués et leur utilisation
CA3054122A1 (fr) 2017-03-02 2018-09-07 Sanwa Kagaku Kenkyusho Co., Ltd. Agent therapeutique pour troubles lies a la consommation d'alcool
JP7218306B2 (ja) * 2017-05-15 2023-02-06 コグニション セラピューティクス インク. 神経変性疾患を治療するための組成物
CN107501272B (zh) * 2017-09-05 2020-03-31 中国药科大学 咪唑并异吲哚类ido1抑制剂、其制备方法及应用
CN111989327A (zh) 2018-02-05 2020-11-24 奥克梅斯公司 用于治疗疼痛的化合物
CN112939844B (zh) * 2019-12-10 2023-02-03 华东师范大学 一种多取代四氢咔唑及其衍生物及其合成方法和应用
CN110938036A (zh) * 2019-12-24 2020-03-31 中国药科大学 一种4-碘-1h-咪唑的制备方法
JP2023524547A (ja) * 2020-05-07 2023-06-12 小野薬品工業株式会社 Kdm5阻害作用を有する3-アザビシクロ(3.1.0)ヘキサン誘導体およびその医薬用途
CN112300002A (zh) * 2020-10-26 2021-02-02 安徽工业大学 一种5-硝基丹皮酚及5-硝基丹皮酚腙的制备方法
CN114057627B (zh) * 2022-01-18 2022-04-01 南京桦冠生物技术有限公司 一种丙型肝炎及新冠药物中间体及其盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872300A (en) * 1956-10-26 1961-07-05 Wellcome Found Improvements in and relating to new derivatives of azabicyclohexane and the manufacture thereof
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
GB948730A (en) * 1959-04-08 1964-02-05 Wellcome Found Substituted cyclopropanes and related compounds
PH24752A (en) 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
MA25035A1 (fr) 2000-07-01
NO20013148L (no) 2001-08-23
DE69932738T2 (de) 2007-08-09
CY1106445T1 (el) 2011-10-12
IS2467B (is) 2008-12-15
ES2274646T3 (es) 2007-05-16
TWI244481B (en) 2005-12-01
HRP20010477A2 (en) 2002-08-31
OA11727A (en) 2004-11-08
AU761574B2 (en) 2003-06-05
US6313312B1 (en) 2001-11-06
EA004672B1 (ru) 2004-06-24
HUP0104816A2 (hu) 2002-04-29
SK8772001A3 (en) 2002-03-05
BR9916584A (pt) 2001-10-16
WO2000039089A1 (fr) 2000-07-06
HK1041698B (zh) 2005-09-02
JP2002533440A (ja) 2002-10-08
SI1140828T1 (sl) 2007-02-28
CN1331679A (zh) 2002-01-16
ID28981A (id) 2001-07-19
AU1069800A (en) 2000-07-31
CZ20012299A3 (cs) 2001-12-12
EP1140828B1 (fr) 2006-08-09
US7049444B2 (en) 2006-05-23
HUP0104816A3 (en) 2002-06-28
AP1852A (en) 2008-05-29
BG105711A (en) 2002-02-28
UY25873A1 (es) 2001-08-27
US20020072616A1 (en) 2002-06-13
DE69932738D1 (de) 2006-09-21
EA200100417A1 (ru) 2001-12-24
JP3553886B2 (ja) 2004-08-11
HRP20010477B1 (en) 2007-03-31
NO20013148D0 (no) 2001-06-22
US20030013875A1 (en) 2003-01-16
IL142697A0 (en) 2002-03-10
EP1140828A1 (fr) 2001-10-10
DK1140828T3 (da) 2006-12-11
ATE335725T1 (de) 2006-09-15
CA2356300C (fr) 2008-12-30
CN1192021C (zh) 2005-03-09
IS5922A (is) 2001-04-20
AP2001002185A0 (en) 2001-06-30
HK1041698A1 (en) 2002-07-19
BG65402B1 (bg) 2008-06-30
DZ2962A1 (fr) 2004-03-15
NZ511234A (en) 2003-09-26
PL348453A1 (en) 2002-05-20
CA2356300A1 (fr) 2000-07-06

Similar Documents

Publication Publication Date Title
NO321658B1 (no) 3-Azabicyklo[3.1.0]heksanderivater som opiatreceptorligander
AU2009247262B2 (en) Amide compound
CA2442114C (fr) N-(2-arylethyl)benzylamines utilisees en tant qu'antagonistes du recepteur 5-ht6
ES2302839T3 (es) Derivados de 3-azabiciclo(3.1.0)hexano como antagonistas de los receptores de opioides.
CA2565200A1 (fr) Modulateurs de raf et methodes d'utilisation
Farr et al. Enantiospecific and regioselective opening of 2-alkyl nosylaziridines by indoles mediated by boron trifluoride. Application to a practical synthesis of a GnRH antagonist
NZ523141A (en) 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
EP3986885B1 (fr) Pyrrolidinamides substitués iv
IL142697A (en) History 3 - Azabicyclo [0.1.3] Haxan, pharmaceutical preparations containing them, process for their preparation and use in the preparation of a drug for the treatment of diseases mediated by opiate receptors
MXPA01006528A (en) 3-azabicyclo[3.1.0.]hexane derivatives as opiate receptors ligands

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees